Evogene Ltd. (NASDAQ:EVGN) Sees Significant Growth in Short Interest

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 65,630 shares, a growth of 32.0% from the December 15th total of 49,723 shares. Based on an average daily trading volume, of 78,479 shares, the short-interest ratio is presently 0.8 days. Approximately 1.3% of the shares of the company are short sold. Approximately 1.3% of the shares of the company are short sold. Based on an average daily trading volume, of 78,479 shares, the short-interest ratio is presently 0.8 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC increased its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,732 shares of the biotechnology company’s stock after acquiring an additional 12,387 shares during the period. Jane Street Group LLC owned approximately 0.63% of Evogene worth $42,000 at the end of the most recent reporting period. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Price Performance

EVGN stock opened at $1.05 on Friday. The firm has a 50-day moving average of $1.10 and a 200 day moving average of $1.21. The company has a market cap of $5.64 million, a P/E ratio of -2.10 and a beta of 1.28. Evogene has a 1 year low of $0.93 and a 1 year high of $2.42.

Evogene (NASDAQ:EVGN) last announced its earnings results on Thursday, November 20th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.10. Evogene had a negative return on equity of 75.09% and a negative net margin of 52.33%.The firm had revenue of $0.31 million during the quarter, compared to analyst estimates of $0.65 million.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

Evogene Company Profile

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.